Effects of Pulmonary Diseases and Their Treatment on Cardiac Function

Sponsor
Ayham Daher
Study ID
NCT05042219
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Cardiac MRI — DIAGNOSTIC_TEST
    Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter

Study Details

While the bidirectional relationship between the lung and the right heart are well studied, the cardiopulmonary interactions between the lung and the left heart are largely unresearched and not well understood. However, in recent years, there is a growing evidence that partially explains the bidirectional interaction between COPD and left heart. Systemic inflammation with multiorgan involvement is thought to play a role in COPD as a systemic disease. Some therapeutic approaches to COPD also appear to influence these cardiopulmonary interactions. While understanding these interactions is very important for clinicians, scientific data are scarce. Cardiac magnetic resonance imaging (cardiac MRI) is the gold standard for assessing cardiac function and dimensions as well as myocardial inflammation. Despite this excellent suitability of cardiac MRI for the assessment of cardiovascular function, only few studies have investigated cardiac function and myocardial structure in patients with pulmonary disease using cardiac MRI. Such a study is therefore very important for understanding the effects of pulmonary disease and its management on the heart. The objective is to determine cardiac function in patients with pulmonary disease and to analyze the cardiovascular effects of the treatment of the pulmonary disease. Specifically, the following will be studied: * Using cardiac MRI: Cardiac function and volumes and indications of myocardial fibrosis and edema in patients with chronic pulmonary disease at the time of first diagnosis. * the vascular function of pulmonary arteries in these patients, also using cardiac MRI * the relationship between pulmonary function parameters and cardiac dysfunction to identify patients at increased risk, if applicable. * Echocardiographic assessment of left heart including strain analysis. * the course of these cardiovascular parameters (using cardiac MRI and echocardiography) 3-6 months after initiation of guideline-based therapy for pulmonary disease.

Key Dates

First listed
Sep 13, 2021
Start date
Jun 1, 2022
Status verified
Jul 2024
Primary completion
Sep 14, 2026
Completion
Dec 14, 2026

Study Design

Enrollment
120 participants (estimated)

Arms

  • Arm: COPD (ICS)
    COPD before initiation of inhaled corticosteroid therapy
  • Arm: COPD (LTOT-NIV)
    COPD before initiation of long term oxygen therapy or domiciliary long-term non-invasive ventilation
  • Arm: COPD (Roflumilast )
    COPD before initiation of Roflumilast therapy
  • Arm: Bronchial asthma (antibody)
    Bronchial asthma before initiation of antibody therapy
  • Arm: Bronchial asthma (ICS)
    Bronchial asthma before initiation of inhaled corticosteroid therapy
  • Arm: Pulmonary fibrosis
    Pulmonary fibrosis before initiation of antifibrotic therapy

Primary Outcome Measure

left-ventricular end-diastolic volume [ Time Frame: 3 months ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsCOPD trialsPulmonology trialsLung disease trials

Related Studies